Contributions
Abstract: EP1353
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Epidemiology
Introduction: Multiple sclerosis (MS) is the commonest cause of neurological disability in young people and is more common in Northern hemisphere. Epidemiological data may be helpful to take decisions about implementation of new services for MS.
Objectives: To get updated data about MS prevalence, incidence and mortality in the Highlands.
Methods: Study population was the population living in the Scottish Highlands. The catchment area covered by NHS Highlands includes North (Wick, Thurso, Brora, Invergordon), Center (Inverness, Avimore, Nairn, Fort William), and West coast (Ullapool, Sky Isle).
Prevalence data was obtained from the MS database at Raigmore hospital (2017). Incidence data was obtained from Scottish MS register and hospital records. The 2010 McDonald criteria were used for those incident patients diagnosed between 1st January and 31st December 2016.
Crude prevalence and incidence rates, and 95% confidence intervals (CI), were calculated assuming a Wilson distribution and standardized against the Scottish population. Cause-specific mortality rates and Case-fatality rate were also analysed.
Results: 745 MS patients were registered in the database. The 75.4% (562 cases) were females, and male-to-female ratio was 1:3. Mean age of population was 54.1±14.1 years. Mean age at diagnosis was 45.4±13.3 years. Mean number of years of evolution since diagnosis was 8.5±4.6 years. Estimated crude prevalence rate was 300 cases per 100,000 inhabitants (95% CI: 280-320).
36 incident new MS cases were registered. The 88.8% were females. Mean age was 40.4±12.1 years. Annual incidence rate in NHS Highlands was 14.4 per 100,000 inhabitants (95% CI: 10.1-19.9).
Mortality rate was 8 MS cases per 1000 MS patients. Cause-specific mortality rate was 3.6 MS deaths per 100,000 population. Case-fatality rate for MS was 25%.
Conclusions: Prevalence and incidence of MS in the Highlands is high. There is an increasing population living longer with MS, and this fact has important implications for resource allocation for MS.
Disclosure: Dr Carod-Artal have participated in advisory boards with Merck, Biogen, Teva, and Novartis, and have received travel grants from Biogen, Sanofi, Merck, Roche, TG Therapeutics and Novartis.
Abstract: EP1353
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Epidemiology
Introduction: Multiple sclerosis (MS) is the commonest cause of neurological disability in young people and is more common in Northern hemisphere. Epidemiological data may be helpful to take decisions about implementation of new services for MS.
Objectives: To get updated data about MS prevalence, incidence and mortality in the Highlands.
Methods: Study population was the population living in the Scottish Highlands. The catchment area covered by NHS Highlands includes North (Wick, Thurso, Brora, Invergordon), Center (Inverness, Avimore, Nairn, Fort William), and West coast (Ullapool, Sky Isle).
Prevalence data was obtained from the MS database at Raigmore hospital (2017). Incidence data was obtained from Scottish MS register and hospital records. The 2010 McDonald criteria were used for those incident patients diagnosed between 1st January and 31st December 2016.
Crude prevalence and incidence rates, and 95% confidence intervals (CI), were calculated assuming a Wilson distribution and standardized against the Scottish population. Cause-specific mortality rates and Case-fatality rate were also analysed.
Results: 745 MS patients were registered in the database. The 75.4% (562 cases) were females, and male-to-female ratio was 1:3. Mean age of population was 54.1±14.1 years. Mean age at diagnosis was 45.4±13.3 years. Mean number of years of evolution since diagnosis was 8.5±4.6 years. Estimated crude prevalence rate was 300 cases per 100,000 inhabitants (95% CI: 280-320).
36 incident new MS cases were registered. The 88.8% were females. Mean age was 40.4±12.1 years. Annual incidence rate in NHS Highlands was 14.4 per 100,000 inhabitants (95% CI: 10.1-19.9).
Mortality rate was 8 MS cases per 1000 MS patients. Cause-specific mortality rate was 3.6 MS deaths per 100,000 population. Case-fatality rate for MS was 25%.
Conclusions: Prevalence and incidence of MS in the Highlands is high. There is an increasing population living longer with MS, and this fact has important implications for resource allocation for MS.
Disclosure: Dr Carod-Artal have participated in advisory boards with Merck, Biogen, Teva, and Novartis, and have received travel grants from Biogen, Sanofi, Merck, Roche, TG Therapeutics and Novartis.